Tags

Type your tag names separated by a space and hit enter

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
J Clin Oncol. 2006 Jan 20; 24(3):460-6.JC

Abstract

PURPOSE

A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib.

PATIENTS AND METHODS

A phase II study of imatinib-combined chemotherapy was conducted for newly diagnosed BCR-ABL-positive ALL in adults. Eighty patients were entered into the trial between September 2002 and January 2005.

RESULTS

Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%. The profile and incidence of severe toxicity were not different from those associated with our historic chemotherapy-alone regimen. Relapse occurred in 20 patients after median CR duration of 5.2 months. Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR. The 1-year event-free and overall survival (OS) rates were estimated to be 60.0%, and 76.1%, respectively, which were significantly better than those for our historic controls treated with chemotherapy alone (P < .0001 for both). Among the current trial patients, the probability for OS at 1 year was 73.3% for those who underwent allogeneic HSCT, and 84.8% for those who did not.

CONCLUSION

Our results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL-positive ALL. Despite a relatively short period of observation, a major potential of this treatment is recognized. Longer follow-up is required to determine its overall effect on survival.

Authors+Show Affiliations

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. myanada@med.nagoya-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16344315

Citation

Yanada, Masamitsu, et al. "High Complete Remission Rate and Promising Outcome By Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia: a Phase II Study By the Japan Adult Leukemia Study Group." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 24, no. 3, 2006, pp. 460-6.
Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460-6.
Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., Maruta, A., Emi, N., Miyazaki, Y., Ohtake, S., Jinnai, I., Matsuo, K., Naoe, T., & Ohno, R. (2006). High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 24(3), 460-6.
Yanada M, et al. High Complete Remission Rate and Promising Outcome By Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia: a Phase II Study By the Japan Adult Leukemia Study Group. J Clin Oncol. 2006 Jan 20;24(3):460-6. PubMed PMID: 16344315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. AU - Yanada,Masamitsu, AU - Takeuchi,Jin, AU - Sugiura,Isamu, AU - Akiyama,Hideki, AU - Usui,Noriko, AU - Yagasaki,Fumiharu, AU - Kobayashi,Tohru, AU - Ueda,Yasunori, AU - Takeuchi,Makoto, AU - Miyawaki,Shuichi, AU - Maruta,Atsuo, AU - Emi,Nobuhiko, AU - Miyazaki,Yasushi, AU - Ohtake,Shigeki, AU - Jinnai,Itsuro, AU - Matsuo,Keitaro, AU - Naoe,Tomoki, AU - Ohno,Ryuzo, AU - ,, Y1 - 2005/12/12/ PY - 2005/12/14/pubmed PY - 2006/2/10/medline PY - 2005/12/14/entrez SP - 460 EP - 6 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 24 IS - 3 N2 - PURPOSE: A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib. PATIENTS AND METHODS: A phase II study of imatinib-combined chemotherapy was conducted for newly diagnosed BCR-ABL-positive ALL in adults. Eighty patients were entered into the trial between September 2002 and January 2005. RESULTS: Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%. The profile and incidence of severe toxicity were not different from those associated with our historic chemotherapy-alone regimen. Relapse occurred in 20 patients after median CR duration of 5.2 months. Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR. The 1-year event-free and overall survival (OS) rates were estimated to be 60.0%, and 76.1%, respectively, which were significantly better than those for our historic controls treated with chemotherapy alone (P < .0001 for both). Among the current trial patients, the probability for OS at 1 year was 73.3% for those who underwent allogeneic HSCT, and 84.8% for those who did not. CONCLUSION: Our results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL-positive ALL. Despite a relatively short period of observation, a major potential of this treatment is recognized. Longer follow-up is required to determine its overall effect on survival. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/16344315/High_complete_remission_rate_and_promising_outcome_by_combination_of_imatinib_and_chemotherapy_for_newly_diagnosed_BCR_ABL_positive_acute_lymphoblastic_leukemia:_a_phase_II_study_by_the_Japan_Adult_Leukemia_Study_Group_ L2 - https://ascopubs.org/doi/10.1200/JCO.2005.03.2177?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -